TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1520755

Group type: EXPERIMENTAL
Intervention: Diet A (animal protein diet)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet V (vegetable protein diet)
Number of subjects: 8
Study: 718514

Group type: EXPERIMENTAL
Intervention: GITS 15/125 (15 mg/hr, administered twice a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional 250‐mg acetazolamide tablets
Number of subjects: 8
Study: 31216955

Group type: EXPERIMENTAL
Intervention: Preconception counseling (six sessions of group counseling)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 152
Study: 30830654

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1200 mg orally before angioplasty
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 90
Study: 28375887

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus blockade
Number of subjects: 156

Group type: COMPARATOR
Intervention: Intraoperative soft‐tissue infiltration of bupivacaine liposome injectable suspension
Number of subjects: 156
Study: 26500462

Group type: EXPERIMENTAL
Intervention: High Protein group (HP) consuming >3 g/kg/d of dietary protein
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal Protein group (NP) consuming 2 g/kg/d of dietary protein
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (NP and HP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High Protein group (HP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal Protein group (NP)
Number of subjects: 48
Study: 24274431

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention using mobile device‐based clinical decision support system
Number of subjects: 15000
Study: 21450630

Group type: EXPERIMENTAL
Intervention: Treadmill training (repetitive intervals to onset of claudication pain, three times a week)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no change in physical activity)
Number of subjects: 68
Study: 19709480

Group type: EXPERIMENTAL
Intervention: Neuromodulation (sacral neuromodulation, tibial nerve stimulation, chemical neuromodulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (behavioral modification and anticholinergic medication)
Number of subjects: 0
Study: 17713332

Group type: EXPERIMENTAL
Intervention: Ozone treatment for 40 seconds
Number of subjects: 102

Group type: COMPARATOR
Intervention: Air treatment for 40 seconds (Control)
Number of subjects: 102
Study: 15107371

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTP) 10 mg intravenously plus placebo intramuscularly
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Metoclopramide-pethidine (M-PET) 10 mg MTP intravenously plus 50 mg pethidine intramuscularly
Number of subjects: 336

Group type: COMPARATOR
Intervention: Pethidine (PET) 50 mg intramuscularly plus placebo intravenously
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo (PLC) intramuscular and intravenous
Number of subjects: 336
Study: 12269647

Group type: EXPERIMENTAL
Intervention: MFNS 200 microg, twice daily
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: MFNS 400 microg, twice daily
Number of subjects: 967

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 967
Study: 9839094

Group type: EXPERIMENTAL
Intervention: Acarbose (25 mg t.i.d. to 100 mg t.i.d. over 24 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8083795

Group type: EXPERIMENTAL
Intervention: Electronic Probe (E.P.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Probe (C.P.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E.P. and C.P. used interchangeably
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electronic Probe (E.P.) and Conventional Probe (C.P.)
Number of subjects: 20
Study: 2910779

Group type: EXPERIMENTAL
Intervention: Intraarterial cis-platinum injection
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous cis-platinum injection
Number of subjects: 9
Study: 805475

Group type: EXPERIMENTAL
Intervention: Triethylenethiophosphoramide
Number of subjects: 826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study: 31658910

Group type: EXPERIMENTAL
Intervention: Clinically diagnosed anorexia nervosa
Number of subjects: 782938

Group type: EXPERIMENTAL
Intervention: Clinically diagnosed bulimia nervosa
Number of subjects: 782938

Group type: EXPERIMENTAL
Intervention: Genetic correlation between anorexia nervosa and bulimia nervosa
Number of subjects: 782938

Group type: EXPERIMENTAL
Intervention: Unique environmental correlation between anorexia nervosa and bulimia nervosa
Number of subjects: 782938

Group type: EXPERIMENTAL
Intervention: Overlap of anorexia nervosa and bulimia nervosa
Number of subjects: 782938
Study: 30721234

Group type: EXPERIMENTAL
Intervention: Educational intervention comprising clinical guidelines, monthly prescribing review meetings, doctor‐patient communication skills training, and education materials for caregivers.
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Educational intervention.
Number of subjects: 1400
Study: 27306985

Group type: EXPERIMENTAL
Intervention: Computer-navigated TKA (NAV)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conventional TKA (CON)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Both groups (NAV and CON)
Number of subjects: 225
Study: 25869112

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy Eating diet
Number of subjects: 120
Study: 23913585

Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 0
Study: 21306953

Group type: EXPERIMENTAL
Intervention: gemcitabine plus axitinib
Number of subjects: 632

Group type: COMPARATOR
Intervention: gemcitabine plus placebo
Number of subjects: 632
Study: 19247240

Group type: EXPERIMENTAL
Intervention: Once-weekly dressing change
Number of subjects: 81

Group type: COMPARATOR
Intervention: Twice-weekly dressing change
Number of subjects: 81
Study: 16464701

Group type: EXPERIMENTAL
Intervention: Multidimensional Anxiety Scale for Children (MASC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: MASC subscales and two MASC items
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: MASC
Number of subjects: 193
Study: 15031566

Group type: EXPERIMENTAL
Intervention: Formoterol 5, 10, 15 and 30 microg twice daily via the Certihaler
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg b.i.d. via the Aerolizer
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 11564594

Group type: EXPERIMENTAL
Intervention: Subcutaneous IL-2 at either 4.5 MIU or 7.5 MIU q12h for 5 days every 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 36
Study: 9784909

Group type: EXPERIMENTAL
Intervention: Acute administration of propionyl-L-carnitine (IV bolus, 30 mg/kg body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronic administration of propionyl-L-carnitine (1.5 mg/d for 1 month)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 30
Study: 7908532

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg and 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg twice daily and 15 mg twice daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg twice daily
Number of subjects: 8
Study: 3198977

Group type: EXPERIMENTAL
Intervention: Tiapamil (lower dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiapamil (higher dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (lower dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (higher dose)
Number of subjects: 0
Study: 30392289

Group type: EXPERIMENTAL
Intervention: Simple CPAP
Number of subjects: 53

Group type: COMPARATOR
Intervention: Traditional CPAP
Number of subjects: 53
Study: 27581221

Group type: EXPERIMENTAL
Intervention: Active NIV
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham NIV
Number of subjects: 54
Study: 24168837

Group type: COMPARATOR
Intervention: TDS (Text Delivery System)
Number of subjects: 150

Group type: COMPARATOR
Intervention: T-CPI (Computer-based Programmed Instruction with Text)
Number of subjects: 150

Group type: COMPARATOR
Intervention: V-CPI (Computer-based Programmed Instruction with Voice)
Number of subjects: 150

Group type: COMPARATOR
Intervention: SA-CPI (Computer-based Programmed Instruction with Static Avatar and Text)
Number of subjects: 150

Group type: COMPARATOR
Intervention: DA-CPI (Computer-based Programmed Instruction with Dynamic Avatar)
Number of subjects: 150
Study: 22655053

Group type: EXPERIMENTAL
Intervention: peginterferon-α2a 180 µg once weekly and ribavirin 800 mg daily
Number of subjects: 303
Study: 21086865

Group type: EXPERIMENTAL
Intervention: Peer-based mentor tutor program (PMTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no PMTP)
Number of subjects: 0
Study: 18545197

Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) 2 g/d for 23 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15954954

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 18
Study: 12548090

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN, 30 mg TID)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pentaerythrityl tetranitrate (PETN, 80 mg TID)
Number of subjects: 18
Study: 10526912

Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive therapy (IT group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Routine antihypertensive therapy (RT group)
Number of subjects: 91
Study: 7574765

Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intra-venous (IV) therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Methotrexate/5‐FU (FMTX) therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: 5‐FU/CDDP (FP) therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FMTX therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: FP therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intra-venous (IV) chemotherapy
Number of subjects: 51
Study: 2117055

Group type: EXPERIMENTAL
Intervention: Oxacillin
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 7398139

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31782966

Group type: EXPERIMENTAL
Intervention: Mobile MI (1 session via mobile phone)
Number of subjects: 300

Group type: COMPARATOR
Intervention: In-person MI (1 session at health center)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Mobile MI (delayed by 1 month)
Number of subjects: 300
Study: 29221491

Group type: EXPERIMENTAL
Intervention: Gantenerumab 105 mg
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Gantenerumab 225 mg
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study: 27397040

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles concurrent cisplatin 50 mg/m(2) and four adjuvant cycles of carboplatin AUC 5 and paclitaxel 175 mg/m(2))
Number of subjects: 686

Group type: COMPARATOR
Intervention: Radiotherapy alone (48·6 Gy in 1·8 Gy fractions five times a week)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 686

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 686
Study: 24788619

Group type: EXPERIMENTAL
Intervention: Initial triple disease-modifying antirheumatic drug therapy (iTDT) with glucocorticoids intramuscularly (arm A)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Initial triple disease-modifying antirheumatic drug therapy (iTDT) with oral glucocorticoids tapering (arm B)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Methotrexate monotherapy (iMM) with oral glucocorticoids (arm C)
Number of subjects: 281
Study: 20449626

Group type: EXPERIMENTAL
Intervention: Metronomic cyclophosphamide (MC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 88
Study: 20546699

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT) for BZ Discontinuation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Taper alone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Taper plus relaxation
Number of subjects: 47
Study: 18179324

Group type: EXPERIMENTAL
Intervention: Dysphoric participants in the easy condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nondysphoric participants in the difficult condition
Number of subjects: 2
Study: 16308444

Group type: EXPERIMENTAL
Intervention: Wobenzym (1 tablet for 6 kg weight, administered for 3 months)
Number of subjects: 27
Study: 12585811

Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 10227638

Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone (500 mg daily for 5 days, with a 10-day tapering period)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone
Number of subjects: 60
Study: 8678176

Group type: EXPERIMENTAL
Intervention: Day hospital/crisis respite care
Number of subjects: 197

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 197
Study: 8457123

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (0.5 g twice a day for 5 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 106

Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate and Placebo
Number of subjects: 106
Study: 3816511

Group type: EXPERIMENTAL
Intervention: Proxen (500 mg twice a day for 60 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day for 60 days)
Number of subjects: 40
Study: 30615071

Group type: EXPERIMENTAL
Intervention: Facilitated Advance Care Planning (ACP) conversations
Number of subjects: 201

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 201
Study: 29361887

Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control case management group
Number of subjects: 0
Study: 27802283

Group type: EXPERIMENTAL
Intervention: Zindagi SMS (daily SMS reminders)
Number of subjects: 2207

Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 2207

Group type: EXPERIMENTAL
Intervention: Zindagi SMS
Number of subjects: 2207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2207
Study: 24992897

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (30 min) during performance (online tDCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anodal tDCS (30 min) before performance (offline tDCS)
Number of subjects: 20
Study: 25091615

Group type: EXPERIMENTAL
Intervention: Controlled cardiovascular exercise (5 sessions a week of 40 minutes each for 10 weeks with a heart rate reserve of 40 to 80%)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 21735214

Group type: EXPERIMENTAL
Intervention: IHH (hyperoxic-hypoxic group) - breathed pure oxygen (F(i)O(2)1.0) for 1 h, followed by hypoxic gas mixture (F(i)O(2)0.15) for 1 h
Number of subjects: 18

Group type: COMPARATOR
Intervention: CON (control group) - breathed normoxic gas mixture (F(i)O(2)0.21) for 2 h
Number of subjects: 18
Study: 19714275

Group type: EXPERIMENTAL
Intervention: Operative treatment with modified Hagie pin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonoperative treatment with sling for comfort
Number of subjects: 57
Study: 17615468

Group type: EXPERIMENTAL
Intervention: Pruritus intervention program (2 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study: 15008768

Group type: EXPERIMENTAL
Intervention: Incremental infusion of oxytocin maintained after 5 cm dilation (Group A)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Incremental infusion of oxytocin discontinued at 5 cm dilation (Group B)
Number of subjects: 104
Study: 11896107

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 9578274

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 102
Study: 8711499

Group type: EXPERIMENTAL
Intervention: Epirubicin/Ifosfamide
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Treatment continuation (Epirubicin/Ifosfamide)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Treatment interruption (control)
Number of subjects: 357
Study: 1925103

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 17
Study: 7114338

Group type: EXPERIMENTAL
Intervention: Periodic screening with mammography and palpation of the breast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study: 31841793

Group type: EXPERIMENTAL
Intervention: Intensive clinicoradiological follow-up
Number of subjects: 2261
Study: 30415601

Group type: EXPERIMENTAL
Intervention: Sacubitril‐valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Enalapril (target dose, 10 mg twice daily)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Sacubitril‐valsartan vs. Enalapril
Number of subjects: 881

Group type: COMPARATOR
Intervention: Sacubitril‐valsartan and Enalapril
Number of subjects: 881
Study: 27538241

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study: 27243927

Group type: EXPERIMENTAL
Intervention: Home telemonitoring device plus standard care
Number of subjects: 1927

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1927
Study: 24896818

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1352
Study: 22287674

Group type: EXPERIMENTAL
Intervention: Nitrate diet (22 g nitrate/kg DM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet (urea added to make isonitrogenous)
Number of subjects: 16
Study: 19056319

Group type: EXPERIMENTAL
Intervention: Written stepwise instruction to optimize the Ramsay Scale
Number of subjects: 45
Study: 17633136

Group type: EXPERIMENTAL
Intervention: Gelofusine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voluven
Number of subjects: 0
Study: 15134973

Group type: EXPERIMENTAL
Intervention: Initial sextant biopsy
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Second screening visit after 4 years
Number of subjects: 728

Group type: COMPARATOR
Intervention: Initial screening round
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Interval cases identified
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Cancers detected
Number of subjects: 728
Study: 11813930

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human NPH insulin
Number of subjects: 0
Study: 9521197

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with acyclovir and/or ganciclovir
Number of subjects: 0
Study: 9420671

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise, Dipyridamole, Adenosine (all modes of stress)
Number of subjects: 20
Study: 1870247

Group type: EXPERIMENTAL
Intervention: Intensive dietetic-hygienic measures and hypolipidemic (mainly clofibrate and/or probucol) and antihypertensive (mainly beta-blockers and/or diuretics) drugs
Number of subjects: 1222
Study: 6751091

Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5% and 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 40
Study: 31214549

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham ESWT (Control)
Number of subjects: 40
Study: 28414899

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2 μg·kg‐1, n = 71)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Oral chloral hydrate (80 mg·kg‐1, n = 70)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Oral chloral hydrate
Number of subjects: 141
Study: 26283669

Group type: EXPERIMENTAL
Intervention: Head cooling for 72 hours starting within 6 hours of birth
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 234
Study: 23327504

Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous-related helping (AAH)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Meeting attendance
Number of subjects: 226
Study: 21721351

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) preconditioning consisting of two 30‐minute intervals of 100% oxygen at 2.4 ATA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) preconditioning
Number of subjects: 81

Group type: COMPARATOR
Intervention: Routine treatment (Control Group)
Number of subjects: 81
Study: 19863880

Group type: EXPERIMENTAL
Intervention: Swan neck catheter (Group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tenckhoff catheter (Group B)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 17200837

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68